This is a paid advertisement for legal services. Sponsor and responsible law firm: JAG Legal Group, using the 1-800-LAW-FIRM brand.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment.

Gabapentin and pregabalin remain FDA-approved for their approved indications. This advertisement is not an FDA notice or a product recall. Research findings do not establish that a medicine caused an individual injury. Jurisdiction and representation disclosures.

LEGAL INFORMATION FOR PATIENTS & FAMILIES Attorney advertising · JAG Legal Group
RESEARCH & SAFETY

October 28 cancer-itch study: what it can and cannot tell us

A new study examined symptom relief and adverse events in cancer care; it does not settle questions about dementia.

JAG Legal Group · Published November 2, 2026

Published November 2, 2026 · Updated November 16, 2026 · Study first published October 28; corrected/typeset November 10, 2026

A different question from dementia risk

The article in The Oncologist, first published October 28 after acceptance October 26 and corrected/typeset November 10, reviewed gabapentinoid treatment for itching in cancer patients. The earlier accepted manuscript and the current typeset abstract display different study-period dates. That discrepancy needs clarification; it should not be used to define an exposure window for patients. The November typeset date does not make this a new clinical study or a new regulatory warning.

What the researchers reported

The single-center retrospective study included 224 patients. Most received pregabalin (80.8%); 19.2% received gabapentin. Researchers reported improvement in itch severity in 90% and adverse events in 14.7%, most commonly sedation. Three patients discontinued treatment because of adverse events.

Keep the medicines and outcomes separate

Gabapentin, including Neurontin, and pregabalin, including Lyrica, are different medicines. Results dominated by pregabalin should not be presented as gabapentin-specific evidence. This study examined itching and recorded adverse events; it was not designed to determine whether either drug causes dementia. Its retrospective design also limits causal conclusions.

What families can take from this

The reason a medicine was prescribed matters when interpreting research. Keep the exact product, indication and treatment dates in your medication record. A symptom-improvement study does not resolve an individual injury allegation or establish legal eligibility. Read our dementia research guide for that separate evidence question. Discuss treatment decisions with your clinician.

YOUR NEXT STEP

You don’t have to sort
through this alone.

Talk through your concerns and learn what information a legal review may require.

Call 1-800-LAW-FIRM ↗

1-800-529-3476 · No obligation to retain a lawyer

Request a reviewCall 1-800-LAW-FIRM ↗